| 0.3143 -0.055 (-14.82%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.83 | 1-year : | 1.2 |
| Resists | First : | 0.71 | Second : | 1.02 |
| Pivot price | 0.66 |
|||
| Supports | First : | 0.21 | Second : | 0.17 |
| MAs | MA(5) : | 0.31 |
MA(20) : | 0.73 |
| MA(100) : | 1.02 |
MA(250) : | 1.73 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 12.2  |
D(3) : | 6.9 |
| RSI | RSI(14): 24.9 |
|||
| 52-week | High : | 8.39 | Low : | 0.21 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NUWE ] has closed above bottom band by 17.1%. Bollinger Bands are 267.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.35 - 0.35 | 0.35 - 0.35 |
| Low: | 0.3 - 0.3 | 0.3 - 0.3 |
| Close: | 0.31 - 0.31 | 0.31 - 0.32 |
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Tue, 10 Jun 2025
Nuwellis Secures $5M Through Public Offering: Complete Details on Stock and Warrant Terms Revealed - Stock Titan
Mon, 09 Jun 2025
Nuwellis (NUWE) Announces Stock Offering, Shares Plummet - GuruFocus
Mon, 09 Jun 2025
Worst performing stock today: Nuwellis (NASDAQ:NUWE) stock down over 34.19% - Markets.com
Mon, 09 Jun 2025
Nuwellis (NUWE) Details Public Offering with Multiple Warrants | NUWE Stock News - GuruFocus
Mon, 09 Jun 2025
Nuwellis Announces Pricing of $4.3 Million Underwritten Public O - GuruFocus
Mon, 09 Jun 2025
Nuwellis Launches Complex $4.3M Public Offering with Multi-Tier Warrant Structure - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 3.1 (%) |
| Shares Short | 62 (K) |
| Shares Short P.Month | 80 (K) |
| EPS | 15.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.81 |
| Profit Margin | -112.1 % |
| Operating Margin | -160.8 % |
| Return on Assets (ttm) | -83.7 % |
| Return on Equity (ttm) | -440.8 % |
| Qtrly Rev. Growth | 2.5 % |
| Gross Profit (p.s.) | 1.3 |
| Sales Per Share | 2.01 |
| EBITDA (p.s.) | -2.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | 0.02 |
| PEG Ratio | 0 |
| Price to Book value | 0.38 |
| Price to Sales | 0.15 |
| Price to Cash Flow | -0.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|